m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05180
 [1]
Non-coding RNA lnc-HZ06 METTL3  lncRNA       miRNA   circRNA Direct Enhancement m6A modification IL1B IL1B METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Interleukin-1 beta (IL1B)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long noncoding RNA HZ06 (Lnc-HZ06) LncRNA View Details
Regulated Target Methyltransferase-like protein 3 (METTL3) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Lnc-HZ06 promotes STAT4-mediated Interleukin-1 beta (IL1B) mRNA transcription, enhances IL1B mRNA stability by promoting the formation of METTL3/HuR/IL1B mRNA ternary complex, and finally up-regulates IL1B expression levels.
Responsed Disease Abortion ICD-11: JA00.09
 Disease Info 
Responsed Drug Benzo[a]pyrene
 Drug Info 
In-vitro Model
Swan 71
 N.A. Homo sapiens CVCL_D855
HTR-8/SVneo Normal Homo sapiens CVCL_7162
In-vivo Model Pregnant C57/BL6 were randomly assigned into four groups (each n=10): (1) corn oil group, (2) BaP group, (3) BaP +AS-NC group, (4) BaP +AS-hz06 group.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Interleukin-1 beta (IL1B) 14 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Glucosamine Approved [2]
Synonyms
Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 439213
TTD: D07NSU
DrugBank: DB01296
 Compound Name Rilonacept Approved [3]
Synonyms
Rilonacept (USAN/INN)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D09DBY
 Compound Name Gallium nitrate Approved [4]
Synonyms
Ganite (TN)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 61635
TTD: D0R4ZT
DrugBank: DB05260
 Compound Name Canakinumab Approved [5]
Synonyms
Ilaris (TN)
    Click to Show/Hide
External Link
TTD: D0TD2G
 Compound Name Diacerein Phase 4 [6]
Synonyms
13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 26248
TTD: D0N1FS
DrugBank: DB11994
 Compound Name XOMA 052 Phase 3 [7]
Synonyms
Gevokizumab
    Click to Show/Hide
External Link
TTD: D0C4KT
 Compound Name LY-2189102 Phase 2 [8]
Synonyms
Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
    Click to Show/Hide
External Link
TTD: D02DJG
 Compound Name ABT-981 Phase 2 [9]
MOA Modulator
External Link
TTD: D01WQQ
 Compound Name AC-201 Phase 2 [10]
MOA Inhibitor
External Link
TTD: D0WP2R
 Compound Name TT-301 Phase 1 [11]
Synonyms
Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 54576073
TTD: D00EHX
DrugBank: DB12899
 Compound Name CYT-013-IL1bQb Phase 1 [12]
Synonyms
Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos
    Click to Show/Hide
External Link
TTD: D09YAS
 Compound Name CDP-484 Discontinued in Phase 1/2 [13]
Synonyms
Anti-IL-1 beta FAb-PEG, Celltech
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05FVX
 Compound Name Celastrol Preclinical [14]
Synonyms
Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid
    Click to Show/Hide
MOA Suppressor
External Link
CID: 122724
TTD: D0I9XH
 Compound Name DVD-Ig Investigative [12]
Synonyms
DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0K8YK
JA00: Abortion 4 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Carboprost Tromethamine Approved [15]
Synonyms
Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine
    Click to Show/Hide
External Link
CID: 5281074
TTD: D07PCI
 Compound Name Dinoprost Tromethamine Approved [16]
Synonyms
Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt
    Click to Show/Hide
External Link
CID: 5282415
TTD: D04RGA
DrugBank: DB01160
 Compound Name GLPG0974 Phase 2 [17]
Synonyms
compound 99 [PMID 25380412]
    Click to Show/Hide
External Link
CID: 57520598
TTD: D0TA4A
DrugBank: DB15406
 Compound Name Epostane Investigative [18]
Synonyms
Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-
    Click to Show/Hide
External Link
CID: 6917713
TTD: D09SWM
References
Ref 1 BaP/BPDE exposure causes human trophoblast cell dysfunctions and induces miscarriage by up-regulating lnc-HZ06-regulated IL1B. J Hazard Mater. 2024 Sep 5;476:134741. doi: 10.1016/j.jhazmat.2024.134741. Epub 2024 Jun 11.
Ref 2 Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98. doi: 10.1002/jcb.22278.
Ref 3 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. doi: 10.1038/nrd2813.
Ref 4 Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and review of actions of gallium III. Med Hypotheses. 2005;65(6):1136-41. doi: 10.1016/j.mehy.2005.06.021. Epub 2005 Aug 24.
Ref 5 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. doi: 10.1038/nrd3101.
Ref 6 [Non-surgical treatment of osteoarthritis of large joints - new aspects]. Wien Med Wochenschr. 2009;159(3-4):76-86. doi: 10.1007/s10354-008-0603-2.
Ref 7 Gevokizumab, an anti-IL-1Beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
Ref 8 Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1Beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013 Aug;36(8):2239-46. doi: 10.2337/dc12-1835. Epub 2013 Mar 20.
Ref 9 Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1Alpha and IL-1Beta. MAbs. 2015;7(3):605-19. doi: 10.1080/19420862.2015.1026501.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
Ref 13 Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334.
Ref 14 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 15 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017989.
Ref 16 Drug information of Dinoprost Tromethamine, 2008. eduDrugs.
Ref 17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8417).
Ref 18 Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med. 1988 Sep 29;319(13):813-7.